Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Asset Writedowns and Impairment (2019 - 2025)

Historic Asset Writedowns and Impairment for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $530000.0.

  • Akebia Therapeutics' Asset Writedowns and Impairment fell 6050.67% to $530000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 844.54%. This contributed to the annual value of $4.2 million for FY2024, which is 16300.0% up from last year.
  • As of Q3 2025, Akebia Therapeutics' Asset Writedowns and Impairment stood at $530000.0, which was down 6050.67% from -$48000.0 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Asset Writedowns and Impairment registered a high of $7.9 million during Q4 2021, and its lowest value of -$9.6 million during Q4 2022.
  • For the 5-year period, Akebia Therapeutics' Asset Writedowns and Impairment averaged around $1.2 million, with its median value being $590000.0 (2024).
  • Per our database at Business Quant, Akebia Therapeutics' Asset Writedowns and Impairment soared by 356906.47% in 2021 and then crashed by 22111.57% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $7.9 million in 2021, then plummeted by 221.12% to -$9.6 million in 2022, then soared by 102.84% to $273000.0 in 2023, then skyrocketed by 561.17% to $1.8 million in 2024, then crashed by 70.64% to $530000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $530000.0 for Q3 2025, versus -$48000.0 for Q2 2025 and $163000.0 for Q1 2025.